Valeant Pharmaceuticals Internat: (NYSE: VRX)

$76.00

0.62 (0.82%)

Volume 616,161

May 21 01:42 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		74.40 - 76.32
	
		52wk Low - High
		42.47 - 78.69
	
		Previous Close
		75.38
	
		Avg. Volume
		1,391,110
	
		Industry
		MED-DRUGS
	
		Market Cap
		22.92 B
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		0.83
	
		PE (Forward)
		13.28
	
		Current Year Est.
		5.68
	
		Quarterly Earnings ESP 
		2.34%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		107 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/17/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            13.28
                        
                            PEG Ratio
                            0.74
                        
                            Current Year Est.
                            5.68
                        
                            Current Quarter Estimate
                            1.28
                        
                            Most Accurate Estimate
                            1.31
                        
                            Earnings ESP 
                            2.34%
                        
                            Next Earnings Report Date
                            08-08-2013
                        
                            EPS Last Year
                            4.63
                        
                            Expected Earnings Growth
                            18.00%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant's development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.   
Full VRX Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
VRX Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	1.28	1.48	5.68	6.53
Number of Estimates	7	7	8	8
Low Estimate	1.19	1.41	5.55	6.14
High Estimate	1.35	1.51	5.89	NA
Year Ago EPS	1.02	1.11	4.40	5.68
EPS Growth	25.07%	33.08%	28.98%	15.02%

More VRX Estimates

Average Earnings Estimates for VRX

EPS Growth for VRX

Industry Analysis

Name	Symbol	Previous Close
VALEANT PHARMA	VRX	75.38
JAZZ PHARMACEUT	JAZZ	58.49
SALIX PHARM-LTD	SLXP	58.75
SANTARUS INC	SNTS	22.10
USANA HLTH SCI	USNA	68.03
BIOCRYST PHARMA	BCRX	1.71
CATALYST PHARMA	CPRX	0.87
CELL THERAPEUT	CTIC	1.22
CUBIST PHARM	CBST	53.48
ELAN CP PLC ADR	ELN	12.04

Sector:Medical>> Industry:MED-DRUGS

COMPARE TICKER vs. Its Peers

Zacks Commentary

Wider-Than-Expected Loss at Anacor

May 13, 2013

QLT Narrows Loss

May 07, 2013

Valeant Misses Earnings and Revenue Estimate in 1Q (Revised)

May 07, 2013

Valeant Beats Earnings, Misses Revs

May 03, 2013

Omeros' OMS721 Files for Orphan Drug Status

Apr 18, 2013

Still Neutral on Mylan

Apr 15, 2013

Actavis Settles with Valeant

Apr 11, 2013

The Zacks Analyst Blog Highlights: Safeway, Valeant Pharmaceuticals, Obagi Medical Products, Allergan and Avanir Pharmaceuticals

Apr 10, 2013

More VRX Zacks Commentary

Financials

EPS TTM	4.63
Sales	3,547
Net Income	-131
Price/Earnings	16.28
Price/Book	6.18
Price/Cash Flow	9.55
Price/Sales	6.14

More VRX Financials

News

/R E P E A T -- Media invitation - Inauguration of Valeant International headquarters in Laval/ - Cnw Group

May 21, 2013

Actavis to Buy Warner Chilcott in $5B Stock Deal - FOXBusiness.com

May 20, 2013

Media invitation - Inauguration of Valeant International headquarters in Laval - Cnw Group

May 20, 2013

Pharma M&A ??? Actavis to Acquire Warner Chilcott - Benzinga

May 20, 2013

Valeant Pharmaceuticals International Earnings Hindsight: Up 8.3% in Last 18 Days (VRX) - Comtex Smartrend(R)

May 20, 2013

Valeant Pharmaceuticals International: The Winning Streak Continues (VRX) - Financial News Netwfork Online - 52-Week High-Lows

May 20, 2013

Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference - Cnw Group

May 20, 2013

Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference - Pr Newswire

May 20, 2013

See All News Stories on VRX

Broker Recommendations

Current ABR	1.71
ABR (Last Week)	1.71
# of recs in ABR	14
Average Target Price	74.27
Industry Rank by ABR	107 out of 265
Rank in Industry	15 out of 91

More VRX Broker Recommendations

Day Low - High	74.40 - 76.32
52wk Low - High	42.47 - 78.69
Previous Close	75.38
Avg. Volume	1,391,110
Industry	MED-DRUGS
Market Cap	22.92 B
Div - Yield	0.00 - 0.00
Beta	0.83
PE (Forward)	13.28
Current Year Est.	5.68
Quarterly Earnings ESP	2.34%

PE (Forward)	13.28
PEG Ratio	0.74
Current Year Est.	5.68
Current Quarter Estimate	1.28
Most Accurate Estimate	1.31
Earnings ESP	2.34%
Next Earnings Report Date	08-08-2013
EPS Last Year	4.63
Expected Earnings Growth	18.00%

Username: Password:

Remember me [?]

Valeant Pharmaceuticals Internat: (NYSE: VRX)

$76.00

0.62 (0.82%)

Volume 616,161

May 21 01:42 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED-DRUGS

Zacks Commentary

Financials

News

Broker Recommendations